| Project/Area Number |
23791005
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Neurology
|
|---|
| Research Institution | Osaka Medical College |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2012: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2011: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
|
|---|
| Keywords | 多発性硬化症 / ω‐3 多価不飽和脂肪酸 / エイコサペンタエン酸 / 実験 的自己免疫性脳脊髄炎 / サイトカイン / 核内受容体 / ω-3多価不飽和脂肪酸 / 実験的自己免疫性脳脊髄炎 / 自己免疫疾患 / 不飽和脂肪酸 |
|---|
| Research Abstract |
We investigated the possible therapeutic effect of eicosapentaenoic acid (EPA), one of ω-3 polyunsaturated fatty acids, for multiple sclerosis (MS) by applying experimental autoimmune encephalomyelitis (EAE), as a model for MS. The clinical scores and the numbers of CNS-infiltrating cells in the EPA-fed mice were significantly lower than those of the non-EPA mice. Additionally, IFN-γ and IL-17 productions were remarkably inhibited and the expression levels of peroxisome proliferator-activated receptors were significantly enhanced in the CNS-infiltrating CD4T cells. Thus ultra-purified EPAshows promise as a potential new therapeutic agent against MS.
|
